Tumor Biology

, Volume 34, Issue 1, pp 387–393 | Cite as

CLEIA CA125 evidences: good analytical performance avoiding “Hook effect”

  • R. Falzarano
  • V. Viggiani
  • S. Michienzi
  • B. Colaprisca
  • F. Longo
  • L. Frati
  • E. Anastasi
Research Article


Cancer antigen 125 (CA125) is a coelomic epithelium-related antigen carried by a high molecular weight glycoprotein complex. It is commonly used as a tumor marker for ovarian cancer to monitor disease progression and response to therapy and as an early detection for recurrence after treatment. The aim of this study was to test the reliability of two different assay methods, a radioimmunometric assay (RIA) and an automated chemiluminescent enzyme immunoassay (CLEIA) system, by measuring CA125 serum levels using both methods in 357 patients and comparing the results. Patients were recruited from Oncologic Unit A, Policlinico Umberto I, Roma. Eighty-six were healthy donors, while 271 were oncologic patients representing a variety of diagnoses. Within this group, 76 patients were diagnosed with an ovarian related pathology (28 cancerous and 48 benign). The evaluation of CA125 marker blood levels showed a high agreement in healthy donors group (R2 = 0.9003). Interesting results emerged when sera collected from oncologic patients were assessed: significant differences between the two assays were found in nine samples. When assayed again with RIA after a dilution, new values agreed with undiluted CLEIA values (R2 = 0.9847). Our data suggest an overall good comparison between the two methods. However, some artifacts were obtained with RIA and indicate an underlying presence of “hook effect”. CLEIA automated assay showed a good reliability and should be preferred to one-step radioimmunoassays in order to minimize errors.


CA125 biomarker Radioimmunoassay Chemiluminescence system 


  1. 1.
    Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem. 2002;48:1151–9.PubMedGoogle Scholar
  2. 2.
    Duffy MJ. Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract. 2012. doi:10.1159/000338393.
  3. 3.
    Kilpatrick ES, Lind MJ. Appropriate requesting of serum tumour markers. BMJ. 2009;339:b3111.PubMedCrossRefGoogle Scholar
  4. 4.
    Suh KS, Park SW, Castro A, Patel H, Blake P, Liang M, et al. Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert Rev Mol Diagn. 2010;10(8):1069–83.PubMedCrossRefGoogle Scholar
  5. 5.
    Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J J Biol Chem. 2001;276(29):27371–5.CrossRefGoogle Scholar
  6. 6.
    Yin BW, Dnistrian A, Lloyd KO. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer. 2002;98(5):737–40.PubMedCrossRefGoogle Scholar
  7. 7.
    Bischof P. What do we know about the origin of CA 125? Eur J Obstet Gynecol Reprod Biol. 1993;49:93–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Kabawat SE, Bast Jr RC, Bhan AK, et al. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol. 1983;2:275–85.PubMedCrossRefGoogle Scholar
  9. 9.
    Walker PL, Crook M. Tumour marker requesting in primary care and the role of the laboratory. J Clin Pathol. 2011;64(5):443–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Bast RC, Klug TL, John St E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309(15):883–7.Google Scholar
  11. 11.
    Pignata S, et al. Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. Ann Oncol. 2011;22(8):viii40–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL, Armstrong DK, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005;23(36):9338–43.PubMedCrossRefGoogle Scholar
  13. 13.
    Granato T, Midulla C, Longo F, Colaprisca B, Frati L, Anastasi E. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumor Biol. 2012. doi:10.1007/s13277-012-0381-8.
  14. 14.
    Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Mark. 1998;13(4):179–87.Google Scholar
  15. 15.
    Midulla C, Manganaro L, Longo F, Viggiani V, Frati L, Granato T, et al. HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma. Tumour Bio. 2012;33(5):1291–8.CrossRefGoogle Scholar
  16. 16.
    Anastasi E, Granato T, Coppa A, Manganaro L, Giannini G, Comploj S, et al. HE4 in the differential diagnosis of a pelvic mass: a case report. Int J Mol Sci. 2011;12(1):627–32.PubMedCrossRefGoogle Scholar
  17. 17.
    Singhal A, et al. Elevation of CA 125 and CA 19-9 in patients with end-stage liver disease. Int J Biol Mark. 2012;27(2):e147–51.CrossRefGoogle Scholar
  18. 18.
    Duffy MJ, Bonfrer JM, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005;15(5):679–91.PubMedCrossRefGoogle Scholar
  19. 19.
    Anthony AM, Ermens AAM, van Duijnhove HLP, et al. Dilution protocols for detection of hook effects/prozone phenomenon. Clin Chem. 2000;46(10):1719–20.Google Scholar
  20. 20.
    McShane LM, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387–91.PubMedCrossRefGoogle Scholar
  21. 21.
    Osman N, et al. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Ir Med J. 2008;101(8):245–7.PubMedGoogle Scholar
  22. 22.
    Hayes Daniel F, et al. A bad tumor marker is as bad as a bad drug: applying scientific principles to tumor biomarker research. Am Assoc Cancer Res Educ Book. 2012;2012(1):139–41.CrossRefGoogle Scholar
  23. 23.
    Colman PG, Di Mario U, Rabizadeh A, Dotta F, Anastasi E, Eisenbarth GS. A prozone phenomenon interferes in islet cell antibody detection: direct comparison of two methods in subjects at risk of diabetes and in insulin dependent diabetics at onset. J Autoimmun. 1988;1(2):109–17.PubMedCrossRefGoogle Scholar
  24. 24.
    Wu JT. Diagnosis and management of cancer using serologic tumor markers. In: Henry JB, editor. Clinical diagnosis and management by laboratory methods. 19th ed. Philadelphia: WB Saunders; 1996. p. 1071.Google Scholar
  25. 25.
    Pesce MA. “High-dose hook effect” with the Centocar CA 125 assay. Clin Chem. 1993;39:1347.PubMedGoogle Scholar
  26. 26.
    Barbati A, Di Renzo GC, Cosmi EV. Hook effect in immunoradiometric assay of CA 125 in peritoneal fluid: evidence of high CA 125 concentrations by a comparative immunoblotting analysis. Clin Chem. 1993;39(7):1548–9.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • R. Falzarano
    • 1
  • V. Viggiani
    • 1
  • S. Michienzi
    • 1
  • B. Colaprisca
    • 1
  • F. Longo
    • 1
  • L. Frati
    • 1
  • E. Anastasi
    • 1
  1. 1.Department of Molecular Medicine“Sapienza” UniversityRomeItaly

Personalised recommendations